How is the Venmax Drugs & Pharmaceuticals Ltd. today?

The Venmax Drugs & Pharmaceuticals Ltd. today is trading in the down by -4.33% at 24.52.

How has Venmax Drugs & Pharmaceuticals Ltd. performed historically?

The Venmax Drugs & Pharmaceuticals Ltd. is currently trading down -4.33% on an intraday basis in the past week the index fell -10.18%. The index has been up 26.39% in the past quarter and rose 486.60% in the past year. You can view this in the overview section.

What is Venmax Drugs & Pharmaceuticals Ltd. Annual Revenue?

Venmax Drugs & Pharmaceuticals Ltd. Annual Revenue rose 836.81%, in the last year to ₹1.86 Cr. Its sector's average revenue growth for the last fiscal year was 9.78%.

What is Venmax Drugs & Pharmaceuticals Ltd. Annual Net Profit?

Venmax Drugs & Pharmaceuticals Ltd. Annual Net Profit fell 116.28% in the last year to ₹0.01 Cr. Its sector's average net profit growth for the last fiscal year was 34.97%.

What is Venmax Drugs & Pharmaceuticals Ltd. Price to Earning Ratio?

Venmax Drugs & Pharmaceuticals Ltd. Price to Earning Ratio is -1,200.78, which is negative.

What is Venmax Drugs & Pharmaceuticals Ltd. Stock Price?

Venmax Drugs & Pharmaceuticals Ltd. Stock Price rose 486.6% and outperformed its sector by 463.18% in the past year.

What is Venmax Drugs & Pharmaceuticals Ltd. Quarterly Net profit?

Venmax Drugs & Pharmaceuticals Ltd. Quarterly Net profit rose 1,627.8% YoY to ₹0.78 Cr. Its sector's average net profit growth YoY for the quarter was 37.15%.

What is Venmax Drugs & Pharmaceuticals Ltd. Debt to Equity Ratio?

Venmax Drugs & Pharmaceuticals Ltd. Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Venmax Drugs & Pharmaceuticals Ltd. Return on Equity(ROE)?

Venmax Drugs & Pharmaceuticals Ltd. Return on Equity(ROE) for the last financial year was -0.23%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Venmax Drugs & Pharmaceuticals Ltd. Mutual Fund Holding?

Venmax Drugs & Pharmaceuticals Ltd. Mutual Fund Holding remained the same in the last quarter at 0%.

What is Venmax Drugs & Pharmaceuticals Ltd. Promoter Share Holding?

Venmax Drugs & Pharmaceuticals Ltd. Promoter Share Holding stayed the same in the most recent quarter at 23.13%.

What is Venmax Drugs & Pharmaceuticals Ltd. Interest Coverage Ratio?

Venmax Drugs & Pharmaceuticals Ltd. Interest Coverage Ratio is -8.62, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

What is Venmax Drugs & Pharmaceuticals Ltd. Promoter Pledges?

Venmax Drugs & Pharmaceuticals Ltd. Promoter Pledges are zero.

Venmax Drugs & Pharmaceuticals Ltd. BSE: 531015 | GSM

Venmax Drugs & Pharmaceuticals Ltd. Live Share Price Today, Share Analysis and Chart

Name: Venmax Drugs & Pharmaceuticals Ltd.: Is Infosys Ltd. worth buying?
Item: Venmax Drugs & Pharmaceuticals Ltd.
Rating: 1.52783325
Author: Trendlyne DVM scores

about

Venmax Drugs & Pharmaceuticals in the business of IT & ITES services.

24.52 -1.11 (-4.33%)

291.07% Gain from 52W Low

10,161 BSE Volume

BSE 03 Jun, 2025 4:01 PM (IST)

Loading... You have run out of DVM views! Check usage

Subscribe now to see details

Not Eligible

Expensive Valuation

1.8 / 100

Technically Neutral

59.3 / 100

No estimates available

Venmax Drugs & Pharmaceuticals Ltd. Live Share Price Today, Share Analysis and Chart

Venmax Drugs & Pharmaceuticals in the business of IT & ITES services.

291.07% Gain from 52W Low

SWOT Analysis

Venmax Drugs & Pharmaceuticals Ltd. Live Price Chart

Earnings Conference Calls, Investor Presentations and Annual Reports

Annual Reports

Venmax Drugs & Pharmaceuticals Ltd. FAQ

How is Venmax Drugs & Pharmaceuticals Ltd. today?

Venmax Drugs & Pharmaceuticals Ltd. today is trading in the red, and is down by -4.33% at 24.52.

How has Venmax Drugs & Pharmaceuticals Ltd. performed historically?

Venmax Drugs & Pharmaceuticals Ltd. is currently trading down -4.33% on an intraday basis. In the past week the stock fell -10.18%. stock has been up 26.39% in the past quarter and rose 486.60% in the past year. You can view this in the overview section.